1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

‘It's Not Sustainable For Companies To Reformulate For One State’ – PCPC’s Karin Ross

 
• By Lauren Nardella

Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.

• Source: Shutterstock

The Modernization of Cosmetics Regulation Act overhauled how cosmetics are regulated at the federal level but left the door open for states to impose their own restrictions on ingredients, and state legislators are using that opening to push bills that go beyond the prohibitions laid out in MOCRA.

Karin Ross, executive VP of government affairs at the Personal Care Products Council, told HBW Insight the cosmetics industry is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 
• By Sarah Karlin-Smith

FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By Lauren Nardella

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.